Ganoderic acid YCAS# 86377-52-8 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 86377-52-8 | SDF | Download SDF |
PubChem ID | 57397445 | Appearance | Powder |
Formula | C30H46O3 | M.Wt | 454.68 |
Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (E,6R)-6-[(3S,5R,10S,13R,14R,17R)-3-hydroxy-4,4,10,13,14-pentamethyl-2,3,5,6,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methylhept-2-enoic acid | ||
SMILES | CC(CCC=C(C)C(=O)O)C1CCC2(C1(CC=C3C2=CCC4C3(CCC(C4(C)C)O)C)C)C | ||
Standard InChIKey | HUTCYUJPLOTDMX-SPPZYOJVSA-N | ||
Standard InChI | InChI=1S/C30H46O3/c1-19(9-8-10-20(2)26(32)33)21-13-17-30(7)23-11-12-24-27(3,4)25(31)15-16-28(24,5)22(23)14-18-29(21,30)6/h10-11,14,19,21,24-25,31H,8-9,12-13,15-18H2,1-7H3,(H,32,33)/b20-10+/t19-,21-,24+,25+,28-,29-,30+/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Ganoderic acid Y significantly inhibits the replication of the viral RNA (vRNA) of EV71 replication through blocking EV71 uncoating. |
Targets | Antifection |
Ganoderic acid Y Dilution Calculator
Ganoderic acid Y Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.1993 mL | 10.9967 mL | 21.9935 mL | 43.987 mL | 54.9837 mL |
5 mM | 0.4399 mL | 2.1993 mL | 4.3987 mL | 8.7974 mL | 10.9967 mL |
10 mM | 0.2199 mL | 1.0997 mL | 2.1993 mL | 4.3987 mL | 5.4984 mL |
50 mM | 0.044 mL | 0.2199 mL | 0.4399 mL | 0.8797 mL | 1.0997 mL |
100 mM | 0.022 mL | 0.11 mL | 0.2199 mL | 0.4399 mL | 0.5498 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 5,8-Epidioxyergosta-6,9(11),22-trien-3-ol
Catalog No.:BCN1327
CAS No.:86363-50-0
- 6-Epiharpagide
Catalog No.:BCN4563
CAS No.:86362-16-5
- Gnetol
Catalog No.:BCN3382
CAS No.:86361-55-9
- Cebranopadol
Catalog No.:BCC1467
CAS No.:863513-91-1
- Medetomidine HCl
Catalog No.:BCC4351
CAS No.:86347-15-1
- Medetomidine
Catalog No.:BCC1736
CAS No.:86347-14-0
- PSI-6206
Catalog No.:BCC3609
CAS No.:863329-66-2
- 8-epi-Chlorajapolide F
Catalog No.:BCN6426
CAS No.:863301-69-3
- Dasatinib monohydrate
Catalog No.:BCN2177
CAS No.:863127-77-9
- Impurity C of Calcitriol
Catalog No.:BCC5384
CAS No.:86307-44-0
- Azilsartan medoxomil monopotassium
Catalog No.:BCC4089
CAS No.:863031-24-7
- Azilsartan Medoxomil
Catalog No.:BCC5021
CAS No.:863031-21-4
- Ganoderic acid X
Catalog No.:BCN7971
CAS No.:86377-53-9
- Diacetoxy-4-gingerdiol
Catalog No.:BCN3337
CAS No.:863780-88-5
- Methyl diacetoxy-6-gingerdiol
Catalog No.:BCN3268
CAS No.:863780-90-9
- Fluconazole
Catalog No.:BCC4905
CAS No.:86386-73-4
- Methoxy-X04
Catalog No.:BCC6331
CAS No.:863918-78-9
- Mc-MMAE
Catalog No.:BCC5201
CAS No.:863971-24-8
- ZIP
Catalog No.:BCC4003
CAS No.:863987-12-6
- Empagliflozin (BI 10773)
Catalog No.:BCC2472
CAS No.:864070-44-0
- GSK429286A
Catalog No.:BCC2532
CAS No.:864082-47-3
- AMG 548
Catalog No.:BCC6084
CAS No.:864249-60-5
- C 021 dihydrochloride
Catalog No.:BCC6047
CAS No.:864289-85-0
- BNTX maleate
Catalog No.:BCC6838
CAS No.:864461-31-4
Antiviral effects of two Ganoderma lucidum triterpenoids against enterovirus 71 infection.[Pubmed:24845570]
Biochem Biophys Res Commun. 2014 Jul 4;449(3):307-12.
Enterovirus 71 (EV71) is a major causative agent for hand, foot and mouth disease (HFMD), and fatal neurological and systemic complications in children. However, there is currently no clinical approved antiviral drug available for the prevention and treatment of the viral infection. Here, we evaluated the antiviral activities of two Ganoderma lucidum triterpenoids (GLTs), Lanosta-7,9(11),24-trien-3-one,15;26-dihydroxy (GLTA) and Ganoderic acid Y (GLTB), against EV71 infection. The results showed that the two natural compounds display significant anti-EV71 activities without cytotoxicity in human rhabdomyosarcoma (RD) cells as evaluated by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell proliferation assay. The mechanisms by which the two compounds affect EV71 infection were further elucidated by three action modes using Ribavirin, a common antiviral drug, as a positive control. The results suggested that GLTA and GLTB prevent EV71 infection through interacting with the viral particle to block the adsorption of virus to the cells. In addition, the interactions between EV71 virion and the compounds were predicated by computer molecular docking, which illustrated that GLTA and GLTB may bind to the viral capsid protein at a hydrophobic pocket (F site), and thus may block uncoating of EV71. Moreover, we demonstrated that GLTA and GLTB significantly inhibit the replication of the viral RNA (vRNA) of EV71 replication through blocking EV71 uncoating. Thus, GLTA and GLTB may represent two potential therapeutic agents to control and treat EV71 infection.
Effect of 26-oxygenosterols from Ganoderma lucidum and their activity as cholesterol synthesis inhibitors.[Pubmed:16000773]
Appl Environ Microbiol. 2005 Jul;71(7):3653-8.
Ganoderma lucidum is a medicinal fungus belonging to the Polyporaceae family which has long been known in Japan as Reishi and has been used extensively in traditional Chinese medicine. We report the isolation and identification of the 26-oxygenosterols ganoderol A, ganoderol B, ganoderal A, and Ganoderic acid Y and their biological effects on cholesterol synthesis in a human hepatic cell line in vitro. We also investigated the site of inhibition in the cholesterol synthesis pathway. We found that these oxygenated sterols from G. lucidum inhibited cholesterol biosynthesis via conversion of acetate or mevalonate as a precursor of cholesterol. By incorporation of 24,25-dihydro-[24,25-3H2]lanosterol and [3-3H]lathosterol in the presence of ganoderol A, we determined that the point of inhibition of cholesterol synthesis is between lanosterol and lathosterol. These results demonstrate that the lanosterol 14alpha-demethylase, which converts 24,25-dihydrolanosterol to cholesterol, can be inhibited by the 26-oxygenosterols from G. lucidum. These 26-oxygenosterols could lead to novel therapeutic agents that lower blood cholesterol.